SCHEMBL3274585

SCHEMBL3274585

CC(C)(C)OC(=O)N1CCN(c2nccc(-c3ccccc3)n2)CC1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACHE P22303 2/20 0.66
CKS1B P61024 2/20 0.59
SKP1 P63208 2/20 0.59
SKP2 Q13309 2/20 0.59
HCAR2 Q8TDS4 1/20 0.56
PTPN11 Q06124 1/20 0.55
GPR119 Q8TDV5 2/20 0.54
CHRNA7 P36544 1/20 0.53
ABCB1 P08183 1/20 0.52
ABCG2 Q9UNQ0 1/20 0.52
SORD Q00796 1/20 0.52
GBA1 P04062 1/20 0.52
DDB1 Q16531 1/20 0.52
CRBN Q96SW2 1/20 0.52
MAPT P10636 1/20 0.51
KIT P10721 1/20 0.51
SLC6A7 Q99884 1/20 0.50
TBK1 Q9UHD2 1/20 0.49
HCRTR1 O43613 1/20 0.48
HCRTR2 O43614 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3651086 0.88 ACHE (0.57) ACHECKS1BSKP1SKP2PTPN11
SCHEMBL27029442 0.85 ACHE (0.55) ACHECKS1BSKP1SKP2PTPN11
SCHEMBL30718211 0.85 ACHE (0.55) ACHECKS1BSKP1SKP2PTPN11
SCHEMBL3268731 0.84 ACHE (0.58) ACHECKS1BSKP1SKP2PTPN11
SCHEMBL30831452 0.84 ACHE (0.57) ACHECKS1BSKP1SKP2PTPN11
SCHEMBL26993891 0.84 ACHE (0.57) ACHECKS1BSKP1SKP2PTPN11
SCHEMBL3268895 0.83 ACHE (0.57) ACHECKS1BSKP1SKP2PTPN11
SCHEMBL16933528 0.83 ABCB1 (0.56) ACHECKS1BSKP1SKP2GPR119
SCHEMBL30718255 0.83 CFTR (0.58) ACHEGPR119CHRNA7DDB1CRBN
SCHEMBL16933529 0.83 ABCB1 (0.56) ACHECKS1BSKP1SKP2GPR119

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8981084-B2 Oxadiazole HDAC inhibitors TEMPERO PHARMACEUTICALS, INC. (US) 2015-03-17 US disclosed
US-8981084-B2 Oxadiazole HDAC inhibitors TEMPERO PHARMACEUTICALS, INC. (US) 2015-03-17 US disclosed
US-8981084-B2 Oxadiazole HDAC inhibitors TEMPERO PHARMACEUTICALS, INC. (US) 2015-03-17 US disclosed
US-20120289495-A1 COMPOUNDS AND METHODS Tempero Pharmaceuticals Inc. 2012-11-15 US disclosed
US-20120289495-A1 COMPOUNDS AND METHODS Tempero Pharmaceuticals Inc. 2012-11-15 US disclosed
US-20120289495-A1 COMPOUNDS AND METHODS Tempero Pharmaceuticals Inc. 2012-11-15 US disclosed
WO-2011088192-A1 COMPOUNDS AND METHODS TEMPERO PHARMACEUTICALS, INC. (US) 2011-07-21 WO disclosed
CN-101981010-A Amide compound TAKEDA PHARMACEUTICAL 2011-02-23 CN disclosed
US-20100234389-A1 AMIDE COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-09-16 US disclosed
EP-2199282-A1 AMIDE COMPOUND Takeda Pharmaceutical Company Limited (JP) 2010-06-23 EP disclosed
US-20090163508-A1 AMIDE COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-06-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100234389-A1 AMIDE COMPOUND FAAH, FAAH2, NAAA ACHE 122/4885CKS1B 3175/4885SKP1 3469/4885
US-20120289495-A1 COMPOUNDS AND METHODS XDH, CCNY, TOP2B ACHE 394/4885CKS1B 1107/4885SKP1 4494/4885
US-20090163508-A1 AMIDE COMPOUND FAAH, FAAH2, NAAA ACHE 122/4885CKS1B 3175/4885SKP1 3469/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.